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Introduction
Duchenne muscular dystrophy (DMD) is the most prevalent 
form of inherited muscular dystrophies, affecting around 1 
in 5,000 newborn boys.1,2 Patients display severe progres-
sive muscular weakness due to the absence of the dystro-
phin protein, which functions as mechanical stabilizer during 
muscle contraction. In the absence of dystrophin, the mus-
cle fibers are easily damaged and are gradually replaced 
by fibrotic and adipose tissues. First symptoms generally 
become apparent at 2–3 years of age, after which, pathology 
develops rapidly. Patients often die before the age of 30 years 
due to respiratory and/or cardiac failure.3
In humans, lack of dystrophin is generally caused by out-
of-frame deletions or small mutations that introduce premature 
stop codons in the DMD gene.4 Several animal models are avail-
able for DMD, among which, the mdx mouse (C57Bl/10ScSn-
DMDmdx/J)—which does not express dystrophin due to a 
premature stop codon in exon 23—is the most widely used.5 
However, the lack of dystrophin is less disastrous in mdx mice 
than in humans. These mice have a nearly normal life expec-
tancy, only slightly impaired muscle function and a better mus-
cle quality compared with DMD patients.6 Nevertheless, this 
mouse model displays several features of the DMD pathology, 
i.e., muscle degeneration and leaky fibers due to the absence 
of dystrophin, and is very useful for preclinical studies.7
During the past several years, a lot of progress has been 
made toward the development of antisense oligonucleotide 
(AON)–mediated exon skipping as a potential therapy targeting 
the underlying genetic defect of DMD. This aims to restore the 
reading frame or bypass a small mutation by skipping one or 
more exons. Thereby, translation can continue and a largely 
functional protein can be formed, as is found in the related, 
but much milder, Becker muscular dystrophy. After obtaining 
proof of principle in vitro in cultured cells and in vivo in animal 
models, clinical trials for AONs with two different backbone 
chemistries, 2′-O-methyl phosphorothioate RNA (2OMePS) 
and phosphorodiamidate morpholino oligomers (PMO), are 
currently ongoing.8 Systemic (subcutaneous, s.c.) treatment 
with drisapersen (2OMePS AON, targeting exon 51) for 5 
weeks induced dystrophin expression in 10 of 12 patients by 
up to 15.6% of levels found in healthy persons.9 Treatment with 
eteplirsen (PMO AON, targeting exon 51) by intravenous (i.v.) 
infusion resulted in dystrophin restoration in 7 of 19 patients at 
highly variable percentages up to 18% of control levels.10 Pla-
cebo-controlled phase 2 and 3 trials have been conducted for 
drisapersen. Encouraging results were reported for the phase 
2 trials, suggesting improved walking distance in 6 minutes for 
treated patients compared with placebo-administered patients 
after 24 and 48 weeks of treatment. However, it was recently 
reported that the primary outcome measure (distance walked 
in 6 minutes) in the phase 3 trial,11 although slightly improved 
in the treated patients, did not differ significantly from the 
placebo-treated patients. More detailed analysis is pending. 
In addition to drisapersen (targeting exon 51), AONs target-
ing other exons, i.e., exons 44, 45, and 53, are under clinical 
evaluation.
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Antisense-mediated exon skipping is currently in clinical development for Duchenne muscular dystrophy (DMD) to amend the 
consequences of the underlying genetic defect and restore dystrophin expression. Due to turnover of compound, transcript, 
and protein, chronic treatment with effector molecules (antisense oligonucleotides) will be required. To investigate the dynamics 
and persistence of antisense 2′-O-methyl phosphorothioate oligonucleotides, exon skipping, and dystrophin expression after 
dosing was concluded, mdx mice were treated subcutaneously for 8 weeks with 100 mg/kg oligonucleotides twice weekly. 
Thereafter, mice were sacrificed at different time points after the final injection (36 hours–24 weeks). Oligonucleotide half-life 
was longer in heart (~65 days) compared with that in skeletal muscle, liver, and kidney (~35 days). Exon skipping half-lives 
varied between 33 and 53 days, whereas dystrophin protein showed a long half-life (>100 days). Oligonucleotide and exon-
skipping levels peaked in the first week and declined thereafter. By contrast, dystrophin expression peaked after 3–8 weeks and 
then slowly declined, remaining detectable after 24 weeks. Concordance between levels of oligonucleotides, exon skipping, and 
proteins was observed, except in heart, wherein high oligonucleotide levels but low exon skipping and dystrophin expression 
were seen. Overall, these results enhance our understanding of the pharmacokinetics and pharmacodynamics of 2′-O-methyl 
phosphorothioate oligos used for the treatment of DMD.
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Because RNA-mediated therapies are subject to clear-
ance and turnover of AONs and the dystrophin transcripts 
and proteins, repeated, lifelong injections will be required to 
maintain therapeutic effects. Therefore, insight into the phar-
macokinetic (PK) and pharmacodynamic properties of these 
compounds is essential to determine how long the effects 
persist and to assess dosing frequencies and regimens. Pre-
vious studies have revealed a plasma half-life for 2OMePS 
AONs of around 4 weeks in patients9 and a tissue half-life of 
2–6 weeks in mdx mouse muscle.12 It has previously been 
observed that uptake of AONs is better in dystrophic muscle 
than in healthy muscle, probably due to the dystrophic “leaky” 
nature of the muscle fibers. Both s.c. and i.v. routes of admin-
istration resulted in muscle uptake and exon skipping, but i.v. 
injections led to much higher AON levels in liver and kidneys, 
although AON levels in muscle were comparable with those 
after s.c. treatment.12 Furthermore, for 2OMePS AONs, exon-
skipping and dystrophin protein levels vary among different 
muscle tissues. Generally, exon-skipping levels in heart are 
lower, whereas the levels are comparable in limb muscle and 
diaphragm.12–17 Increase in exon skipping and accumulation 
of dystrophin protein were seen up to 12 weeks of treatment, 
and long-term treatment for 6 months has been shown to be 
feasible.13,15 Comparison of various maintenance regimens 
revealed that 8 weeks after the final dose, the decline in AON 
levels was faster than the decline in exon-skipping and pro-
tein levels, indicating differences in turnover.17 However, the 
relation between clearance and turnover of the compound, 
the induced skipped transcript, and restored dystrophin pro-
tein and long-term analysis of the persistence of different 
effects after s.c. treatment have not been studied. In order 
to expand our understanding of the PK/pharmacodynamic 
relationship of 2OMePS AONs, mdx mice, in which the muta-
tion can be bypassed by skipping exon 23, were dosed with 
100 mg/kg twice weekly for 8 weeks via the s.c. route, after 
which, tissues were harvested at different time points for the 
analysis of 23AON, exon-skipping, and protein levels.
Results
Dynamics of 23AON levels in plasma, muscle, and organs
To investigate the dynamics of the effects induced by treat-
ment with 2OMePS AONs, mice were treated subcutane-
ously with 100 mg 23AON/kg body weight twice weekly for 
8 weeks. Six mice per group were sacrificed at different time 
points after the final injection, ranging from 36 hours up to 24 
weeks. To assess the uptake, turnover, and clearance of AON 
in plasma and in different tissues, 23AON levels were deter-
mined with an AON-specific hybridization-ligation assay, and 
average results were calculated (Figure 1; Table 1). For all 
tissues, this revealed a decline in AON levels after the final 
injection, and 23AON was still detectable in muscle, liver, 
and kidney after 24 weeks (on average, around 5–10% of 
the 23AON levels at 36 hours). Terminal half-lives ranged 
from 28 days in triceps to 65 days in heart (Table 1). The 
half-life in heart was much longer than that in the other tis-
sues. Although the terminal half-life in diaphragm was com-
parable with that in liver and kidney, it was slightly shorter in 
limb muscles (quadriceps and triceps) and comparable with 
that found in plasma. As observed previously,12 AON levels 
were higher in liver and kidney than in muscle. When com-
paring the different muscles with each other, 23AON levels 
were higher in diaphragm and heart than in limb muscles (P 
< 0.05). No differences were observed in 23AON levels when 
comparing liver and kidney. Oligonucleotide levels in plasma 
decreased rapidly after the final dose, and by 24 weeks, 
23AON was barely detectable, with levels in only two out of 
six mice reaching the limit of detection.
Dynamics of exon-skipping levels in muscle
The exon 23–skipping levels were determined in several 
limb muscles, diaphragm, and heart (Figure 2; Table 2). 
Exon-skipping levels were highest at the early time points 
(36 hours and 1 week after final AON injection) and declined 
thereafter. Exon-skipping levels were significantly lower in 
heart compared with those in skeletal muscle (P < 0.01). 
After 24 weeks, skipping was undetectable in all samples. No 
large differences in rate of decline between individual mus-
cles were observed, considering the interindividual variations 
within a tissue and the variations in half-life between 33 and 
53 days.
Dynamics of dystrophin protein expression
Restoration of dystrophin protein expression after AON treat-
ment was detectable at each time point in the quadriceps and 
diaphragm (Figure 3; Table 2). No dystrophin was observed 
for untreated mdx mice (data not shown). In treated mus-
cles, dystrophin levels were initially low, peaked somewhere 
between 3 and 8 weeks after the final injection for both dia-
phragm and quadriceps, and then slowly declined. Levels in 
diaphragm were and remained significantly (P < 0.01) higher 
Figure 1  23AON levels in plasma, muscle, and other organs 
over time. A hybridization-ligation assay was used to determine 
23AON levels in plasma, muscle, and organs at different time points 
ranging from 36 hours up to 24 weeks after the final injection. Data 
are represented on a logarithmic scale. Each dot represents an 
individual measurement, and lines are fitted through the averages 
for each tissue. AON, antisense oligonucleotide.
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than those in quadriceps and also were slightly more stable, 
with half-lives of ~100 and 130 days, respectively. In heart, 
no dystrophin protein levels >0.5% could be detected (data 
not shown).
Correlation among 23AON levels, exon skipping, and 
protein expression
For the majority of muscles analyzed, a correlation among 
23AON levels, exon skipping, and protein expression was 
observed. The highest 23AON levels were observed in the 
diaphragm, resulting in highest exon skipping and dystrophin 
protein expression. Lower 23AON levels were observed in 
quadriceps and triceps, resulting in exon-skipping levels that 
were, at most time points analyzed, slightly lower than or 
comparable with exon-skipping levels in the diaphragm. Fur-
thermore, the level of dystrophin protein expression in quad-
riceps was lower than the corresponding value observed in 
diaphragm. By contrast, this correlation was not observed 
in heart, wherein 23AON levels were relatively high (com-
parable with diaphragm), while exon-skipping levels were 
significantly lower than those in skeletal muscle; moreover, 
dystrophin protein expression was also very low.
When comparing patterns of the different parameters, 
both 23AON and exon-skipping levels peaked shortly after 
treatment, within the first week, and thereafter showed 
a similar declining pattern, whereas the profile of dystro-
phin protein expression was shifted, peaking a few weeks 
after treatment and displaying a more prolonged effect 
(Figure 4).
Discussion
AON-mediated exon skipping is currently in advanced 
stages of clinical development as a potential therapy for 
DMD aiming to partly correct consequences of the genetic 
defect. However, due to clearance of AONs, skipped tran-
scripts, and restored dystrophin protein, chronic treatment 
will be required. One way to try and prolong the effect is to 
deliver antisense sequences using (viral) vectors in order to 
achieve a stabler expression of the AONs. Adenoassociated 
virus–expressing modified small nuclear ribonucleoprotein 
particles, i.e., U1 and U7 small nuclear ribonucleoprotein 
particles, in which the small nuclear RNA is replaced by the 
desired AON sequence, have shown to induce long-term 
dystrophin rescue in the mdx mouse.18 This approach has 
also been proved to result in long-term cardiac expression of 
dystrophin in the Golden retriever muscular dystrophy dog,19 
harboring a deletion of exon 7, requiring skipping of exons 
6 and 8 to restore the reading frame.20 Drawbacks of using 
adenoassociated viruses as vectors are toxicity concerns 
and the possibility of an immune response against the viral 
vector, resulting in the loss of transduced fibers.21 A recent 
5-year follow-up study in Golden retriever muscular dystrophy 
dogs did not show immune rejection; however, after 5 
years, disappearance of dystrophin protein expression was 
observed, probably due to instability of the newly formed 
protein.22 The same was observed in a study in mdx mice, 
wherein it was shown also shown that adenoassociated 
virus vectors and transgene expression were lost quicker 
from dystrophic muscle than from healthy muscle.23 There-
fore, repetition of treatment would still be required, which is 
not possible due to immunization against the adenoassoci-
ated virus after the first injection. This makes it unlikely that 
this approach will be clinically applicable in the near future. 
Thus, the AON approach is more viable in the short term, 
which involves repeated injections, and knowledge about 
the PK and pharmacodynamic effects is, therefore, valu-
able. The detailed longitudinal analysis of different muscles, 
kidney, and liver is ethically and practically challenging in 
humans but more straightforward in mice. In this study, the 
clearance/turnover of AON, transcript, and protein over time 
in mdx mice after treatment with 2OMePS AON, one of the 
Table 1 Average AON levels at each time point per tissue and terminal half-life for each tissue
Time (week)
23AON levelsa
Plasma Quadriceps Triceps Diaphragm Heart Liver Kidney
0.2 0.462 (±0.205) 32.3 (±9.1) 33.0 (±5.6) 54.3 (±11.4) 49.1 (±9.0) 477.0 (±49.7) 655.7 (±419.9)
1 0.245 (±0.183) 33.9 (±16.3) 28.2 (±4.6) 51.1 (±16.3) 40.7 (±10.5) 456.1 (±101.3) 479.7 (±437.9)
3 0.236 (±0.119) 18.8 (±6.1) 18.3 (±6.6) 40.5 (±12.5) 40.6 (±9.2) 510.9 (±119.6) 289.6 (±200.3)
8 0.137 (±0.092) 8.9 (±5.1) 5.7 (±1.7) 18.1 (±12.9) 13.3 (±1.6) 270.1 (±109.3) 160.1 (±155.0)
12 0.052 (±0.041) 2.9 (±1.2) 2.0 (±0.7) 6.4 (±2.5) 10.2 (±2.0) 142.7 (±29.1) 70.3 (±44.5)
24 0.008 (±0.004) 0.8 (±0.6) 0.5 (±0.2) 4.7 (±0.7) 4.0 (±0.7) 50.4 (±10.2) 20.1 (±7.2)
Terminal half-life (days) 30 32 28 45 65 48 38
a23AON (antisense oligonucleotide) levels are expressed as µg/ml for plasma and µg/g tissue for muscle and other organs (mean (± SD)).
Figure 2 Exon-skipping levels in different muscles over time. (a) 
Representative example of an reverse transcription–polymerase 
chain reaction (RT–PCR) analysis for the quadriceps. Unskipped 
product consists of 334 base pairs and exon 23 skipping results in 
a 121-base pair product. “PCR ctrls” indicates PCR controls, M is 
marker. (b) Quantification of exon 23–skipping levels by RT–PCR 
analysis at several time points after the final 23AON injection. Data 
are represented as mean ± SD. AON, antisense oligonucleotide.
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two background chemistries mainly used in clinical trials, 
was studied.
First of all, the decline in 23AON levels over time was stud-
ied in plasma, muscle, and other organs following s.c. injec-
tions. After injection, AON levels in plasma decline rapidly 
due to uptake by organs and because of clearance, which 
occurs primarily through the kidney. For 2OMePS AONs, 
this is partly modulated by the plasma protein binding prop-
erties of the phosphorothioate backbone of the AONs, but 
when high doses are injected exceeding the binding capac-
ity, unbound AONs will be cleared rapidly.24,25 The first time 
point analyzed was 36 hours after the final injection, the time 
point when previous studies indicated that the majority of the 
plasma clearance has already occurred.17 The mean half-life 
determined for 23AONs in mice (30 days) was comparable 
with that observed for 51AON in patients (29 days).9 When 
comparing different muscle types, higher 23AON levels in 
diaphragm and heart were observed, whereas the longest 
terminal half-life was found in heart. This was probably 
due to reduced AON turnover because the turnover rate 
of cardiac muscle cells is much slower than that of skeletal 
muscle fibers (especially dystrophic skeletal muscle fibers). 
This is in line with previous observations of a longer half-
life of AONs in heart compared with that in skeletal muscle. 
In the previous study, a markedly shorter half-life in triceps 
(~10 days) was observed compared with that in quadriceps 
(~33 days), whereas in the current study, half-lives are com-
parable (~30 days). Furthermore, the currently calculated 
half-life in heart is longer (65 days versus 46 days).12 These 
discrepancies are probably due to the fact that in the previ-
ous study, only four time points up to 14 days after the final 
injection were measured, consisting of two mice per time 
point, making the estimations less accurate. Furthermore, 
in the previous study, i.v. injections were used, which show 
higher levels of AON uptake by the kidney and liver,12 which 
can also have contributed to the observed differences. As 
Table 2 Average exon-skipping and protein levels at each time point per muscle and terminal half-life for each muscle
Time (week)
Exon-skipping levelsa Protein levelsb
Quadriceps Triceps Diaphragm Heart Quadriceps Diaphragm
0.2 11.3 (±1.3) 11.2 (±2.6) 11.3 (±2.4) 4.1 (±0.5) 0.61 (±0.23) 2.36 (±0.49)
1 9.7 (±2.1) 8.7 (±1.9) 11.7 (±2.7) 3.2 (±0.7) 0.95 (±0.13) 1.93 (±0.52)
3 6.9 (±2.2) 9.4 (±1.6) 10.6 (±3.4) 2.7 (±0.5) 1.31 (±0.63) 2.43 (±0.85)
8 5.7 (±2.4) 2.8 (±1.0) 8.6 (±0.5) 0.9 (±0.7) 0.91 (±0.44) 2.75 (±1.21)
12 3.1 (±1.3) 2.2 (±1.7) 3.7 (±1.6) 1.0 (±0.3) 0.56 (±0.38) 2.42 (±0.99)
24 ND ND ND ND 0.39 (±0.19) 1.57 (±0.63)
Terminal half-life (days) 53 33 49 39 103 137
ND, not detectable.
aExon 23–skipping levels are expressed as skipped transcript as percentage of total transcript (mean (± SD)). bDystrophin protein levels are expressed as 
percentage of wild-type levels in the same muscle (mean (± SD)).
Figure 3 Dystrophin protein levels in muscle over time. (a) 
Representative examples of western blot analyses for the diaphragm 
showing low levels of dystrophin protein (top) at all analyzed 
time points. As loading control, α-actinin (bottom) was used. (b) 
Quantification of dystrophin protein levels, detected by western blot 
analysis. Data are represented as mean ± SD for each tissue.
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Figure 4 Comparison of time effects at different levels. Comparison 
of time course of 23AON levels, exon skipping, and protein 
expression after the final injection for (a) quadriceps and (b) 
diaphragm. Data are represented as percentages of levels observed 
at time point t = 36 hours (set at 100%) for 23AON, exon-skipping, 
and protein levels separately. Error bars represent the SD. AON, 
antisense oligonucleotide.
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expected, AON levels in liver and kidney were much higher 
than those in muscle. It has been noticed before that for 
2OMePS AONs, levels are similar in liver and kidney,14 and 
here it is shown that the decline pattern is comparable too. 
Unfortunately, when comparing the terminal half-lives in the 
nontarget organs (liver and kidney) with those in the tar-
geted organ (muscle), half-lives were slightly shorter in limb 
muscles compared with those in liver and kidney. A longer 
muscle half-life would have been advantageous for plan-
ning off-treatment periods, e.g., to prevent accumulation of 
compounds in liver and kidney. Nevertheless, the absolute 
reduction of AON levels in liver and kidney is greater than 
that in muscles.
Second, exon-skipping levels were determined in several 
skeletal muscles and the heart. Here, highest levels were 
also observed shortly after the final injection (within the first 
week), whereupon they declined in a similar pattern as the 
23AON levels. For diaphragm, the higher 23AON levels were 
also accompanied by high exon-skipping levels, whereas by 
contrast, this correlation was not observed in heart. wherein, 
although 23AON levels were relatively high (comparable with 
diaphragm), exon-skipping levels were significantly lower 
than those in skeletal muscle.
Third, dystrophin protein levels were determined. These 
showed a delayed pattern, peaking a few weeks later, 
compared with AON and exon-skipping levels. Importantly, 
although levels were low in general, dystrophin protein 
expression was observed up to 24 weeks. Wu et al. deter-
mined the half-life of the dystrophin protein in mdx mice 
after a single i.v. injection with peptide-conjugated PMOs 
(pPMOs) targeting exon 23. This resulted in a protein half-life 
of ~2 months for skeletal muscles, and levels had dropped 
to around 10% after 5 months.26 The half-lives measured in 
our experiments were a bit longer (3–4 months), resulting 
in a smaller decrease in dystrophin levels; 30–50% of ini-
tial levels were still observed after ~5 months (levels at 24 
weeks compared with peak levels) in both muscles. A pos-
sible explanation is the difference in experimental setup and 
backbone chemistry of the AONs between both studies. In 
this study, 2OMePS AONs were used, whereas the study of 
Wu et al. used pPMOs. These two chemistries probably have 
a different biodistribution pattern, as was also seen between 
2OMePS AONs and naked PMOs.14 Because AON PKs were 
not measured in the study of Wu et al., it is not known how 
much AON remained in the muscle to induce further exon 
skipping and dystrophin production, resulting in differences 
over time. Furthermore, Wu et al. only used a single AON 
injection, whereas mice were treated for a longer period in 
our study. A single injection is more likely to give variation 
in AON levels between mice, which influences the precise-
ness of the half-life estimations. Therefore, both results are 
not directly comparable. Unfortunately, dystrophin protein 
was barely detectable in heart. This was also seen in a study 
using PMO AONs, wherein dystrophin expression could be 
detected in all analyzed muscles, except for the heart, after 
7 weeks of treatment.27 Probably, overall, higher skipping 
levels and/or longer treatment times are needed for protein 
restoration. This is underlined by the fact that after 6 months 
of weekly treatment with 200 mg/kg, dystrophin was readily 
detectable in heart.15
Overall, there was a good correlation between AON effects 
at different levels. In diaphragm, the higher 23AON levels 
were accompanied by higher exon-skipping levels and pro-
tein expression. Only in heart, the higher 23AON levels did 
not result in higher exon-skipping and protein levels. This 
can be explained by inherent differences between cardiac 
and skeletal muscle. As mentioned before, skeletal muscles 
become permeable in the absence of dystrophin, facilitat-
ing the uptake of AONs. The heart is built up of individual 
cardiomyocytes, which do not display this leakiness, thereby 
making it harder for AONs to get inside.12,28 The assay used 
for determination of 23AON levels does not discriminate 
between AON inside the heart as whole organ and AON that 
is actually inside the cardiomyocytes. Therefore, the presence 
of higher 23AON levels, but lower exon-skipping levels, sug-
gests that in heart, the majority of AON is probably located in 
the interstitium and therefore ineffective. This might also be 
the reason why, although low 23AON levels were still detect-
able after 24 weeks, no exon skipping could be observed at 
this time point. Other possibilities are that this is due to dif-
ferences in sensitivity of the assay used for determination of 
AON levels versus those for determining exon-skipping lev-
els or that the low AON levels are insufficient to induce exon 
skipping. Expression percentages for dystrophin protein are 
much lower than those for exon skipping. This is usually seen 
for both 2OMePS15,17 and PMO/pPMO AONs,14,26,29,30 and this 
discrepancy can be explained by the fact that exon-skipping 
levels are compared with the total transcript levels in the mdx 
mouse, whereas dystrophin protein levels are compared with 
wild-type dystrophin levels. It has been reported that com-
pared with wild-type dystrophin transcripts, a 5′-to-3′ imbal-
ance exists for mdx dystrophin transcripts. This means that 
not all mdx dystrophin transcripts are complete and cannot 
be translated into dystrophin protein.31
In conclusion, 23AON and exon-skipping levels show 
a similar decline pattern over time after the final injection. 
Exon skipping is not detectable after 6 months, but its effects 
on dystrophin protein restoration remain quite stable. After 
treatment, AONs are taken up by muscles and other organs, 
partly leading to immediate excretion without inducing further 
effects and partly leading to exon skipping inside the muscle 
fibers. Thereafter, new dystrophin protein can be formed, 
which displays a long half-life. The differences in rates of turn-
over of the compound itself, RNA, and the protein influence 
these effects, in addition to differences in composition and 
amount of degeneration and regeneration between different 
muscle groups. Our results provided further insight into how 
these processes interact and are thus useful for studying the 
long-term effects of AON treatment.
Materials And Methods
All experiments were approved by the local ethical committee 
for animal experiments of the Leiden University Medical Cen-
ter. Mice were housed in individually ventilated cages in the 
animal facility of the Leiden University Medical Center and 
received food and drink ad libitum. Moreover, the mdx mice 
for the study (C57Bl/10ScSn-DMDmdx/J) were obtained from 
our own breeding facility.
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Treatment of mdx mice with 23AON and sample preparation. 
Starting at an age of 3–4 weeks, 36 mdx mice were treated 
subcutaneously with 100 mg of 23AON/kg body weight in 
100 µl saline twice weekly for 8 weeks. The 23AON mole-
cule, previously described as M23D(+2–18), is a 2′-O-methyl 
phosphorothioate RNA oligonucleotide with a full-length 
phosphorothioate backbone, specifically targeting exon 2332 
(Prosensa Therapeutics, Leiden, the Netherlands). Mice were 
sacrificed by cervical dislocation at different time points after 
the final injection: t = 36 hours and 1, 3, 8, 12, and 24 weeks 
(6 mice (3 males, 3 females) per time point). Before sacri-
fice, blood samples were taken for plasma PK analysis (see 
below). Plasma was generated by centrifuging at 18,000g for 
5 minutes and it was stored at −80 °C until analysis. After 
sacrifice, muscles (triceps, tibialis anterior, quadriceps, heart, 
and diaphragm) and liver, kidney, and spleen were isolated, 
snap-frozen in liquid nitrogen–cooled 2-methylbutane, and 
stored at −80 °C.
Assessment of 23AON levels with a hybridization-ligation 
assay. An assay based on a previously published hybrid-
ization-ligation assay was used for the determination of the 
23AON level in different tissues at Prosensa Therapeutics.33 
Tissues were homogenized in 100 mmol/l Tris–HCl (pH 8.5), 
200 mmol/l NaCl, 0.2% sodium dodecyl sulfate, 5 mmol/l eth-
ylenediaminetetraacetic acid, and 2 mg/ml protK using zirco-
nium beads (1.4 mm; OPS Diagnostics, Lebanon, NJ) in a 
MagNA Lyser (Roche Diagnostics, Almere, the Netherlands) 
according to manufacturer’s protocol. Plasma samples were 
diluted tenfold, muscle samples 500 and 1,000 times, and 
organs 1,000 and 5,000 times in pooled control mdx tissue 
in phosphate-buffered saline. A signal probe (containing the 
peptide for antibody recognition) and a template (comple-
mentary to 23AON and the probe) were added to homog-
enized samples. Only when both 23AON and probe are 
bound to the template, a ligation step will take place. After 
this step and washing away of the unbound probe, enzyme-
linked antibodies were used to detect the amount of probe–
23AON. Calibration curves of the analyzed 23AON prepared 
in 10% pooled plasma or in pooled control mouse mdx tissue 
in phosphate-buffered saline were used to quantify 23AON. 
All analyses were performed in duplicate.
RNA extraction and analysis of exon skipping by reverse tran-
scription–polymerase chain reaction. Muscles were homog-
enized in TriPure isolation reagent (Roche Diagnostics) using 
zirconium beads (1.4 mm; OPS Diagnostics) by grinding in a 
MagNA Lyser (Roche Diagnostics). Total RNA was extracted, 
and 600 ng was used for reverse transcription–polymerase 
chain reactionanalysis. Complementary DNA was generated 
by incubating at 42 °C for 45 minutes with random hexamer 
primers (20 ng/µl) and Transcriptor reverse transcriptase poly-
merase (Roche Diagnostics) in 20 µl. Subsequently, 2 µl of 
complementary DNA was amplified in a 50-µl polymerase 
chain reaction reaction with 30 cycles of 94 °C for 30 sec-
onds, 60 °C for 30 seconds, and 72 °C for 30 seconds, as pre-
viously described.34 PCR products were visualized on 1.5% 
agarose gels and quantified using a DNA high-sensitivity chip 
on the LabChip GX, in combination with the LabChip GX soft-
ware (Caliper Life Sciences, Teralfene, Belgium).
Analysis of dystrophin protein expression by western blot. 
Muscles were minced in treatment buffer containing 75 
mmol/l Tris–HCl (pH 6.8)–15% (w/v) sodium dodecyl sulfate 
using zirconium beads (1.4 mm; OPS Diagnostics) or MagNA 
Lyser green beads (Roche Diagnostics) in a BBY24M Bul-
let Blender Storm (Next Advance, Averill Park, NY). Protein 
concentrations were determined using a Pierce bicinchoninic 
acid protein assay kit (Thermo Fisher Scientific, Waltham, 
MA) according to manufacturer’s instructions. Samples con-
taining 30 µg of protein were made in treatment buffer with 
20% (v/v) glycerol, 5% (v/v) β-Mercaptoethanol, and 0.001% 
(w/v) Bromophenol blue and heated for 5 minutes at 95 °C. 
Wild-type control samples containing 10%, 3.3%, 1.1%, 
and 0.4% of protein were used as reference. Samples were 
loaded on 1.0-mm-thick native polyacrylamide Tris-acetate 
gels, with a linear resolving gel gradient of 3–8% (BioRad, 
Veenendaal, the Netherlands) and run on the Trans-Blot 
Turbo system for 1 hour at 75 V (0.07 A) and for 2.5 hours at 
150 V (0.12 A) in an ice container. Proteins were blotted onto 
a nitrocellulose membrane using the ready to use Trans-Blot 
Turbo transfer packs in combination with the Trans-Blot Turbo 
transfer system (BioRad) at 2.5 A and ~25 V for 10 minutes. 
Membranes were blocked in 10 mmol/l Tris–HCl (pH 8) and 
0.15 mol/l NaCl (Tris-buffered saline (TBS))–5% nonfat dried 
milk (Elk, Campina Melkunie, Zaltbommel, the Netherlands) 
and washed in TBS–0.05% (v/v) Tween20 (TBST). Mem-
branes were incubated overnight with 1:125 NCL-Dys1 (Dy4; 
NovoCastra, Newcastle Upon Tyne, UK) and α-actinin was 
used as loading control (1:7,500; AB72592; Abcam, Cam-
bridge, UK) in TBS. The next day, membranes were washed 
in TBST, incubated 1 hour with the fluorescent secondary 
antibodies IRDye 800CW goat-α-mouse IgG (1:5,000; Li-
Cor; NE) and IRDye 680LT donkey-α-rabbit IgG (1:10 000; 
Li-Cor) in TBS, washed in TBST and TBS, and analyzed with 
the Odyssey system and software (Li-Cor) (M. Hulsker et al., 
manuscript in preparation).
Statistical analysis. For 23AON levels, individual data are 
represented for each measurement, and exponential curves 
were fitted for each tissue. For exon-skipping and protein 
levels, data are represented as mean ± SD for each tissue. 
PK plasma parameters (terminal half-lives of the molecule in 
plasma and tissue) were derived by noncompartmental anal-
ysis using Phoenix WinNonLin software (version 6.2; Phar-
sight, Mountain View, CA). For samples in which 23AON was 
not detectable, values were set at 50% of limit of quantifica-
tion of mouse 23AON in neat plasma (i.e., 50% of 0.011 µg/
ml). For statistical testing, SPSS version 20.0 (IBM, Armonk, 
NY) was used. A P value ≤0.05 was considered significant.
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